Journal of surgical oncology, 2018-07, Vol.118 (1), p.77-85
2018
Details
- Autor(en) / Beteiligte
- Titel
- Checkpoint blockade in esophagogastric cancer
- Ist Teil von
- Journal of surgical oncology, 2018-07, Vol.118 (1), p.77-85
- Ort / Verlag
- United States: Wiley Subscription Services, Inc
- Erscheinungsjahr
- 2018
- Link zum Volltext
- Quelle
- Wiley Online Library Journals Frontfile Complete
- Beschreibungen/Notizen
- There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second‐line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD‐1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second‐line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0022-4790eISSN: 1096-9098DOI: 10.1002/jso.25116Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7891842
- Format
- –
- Schlagworte
- Adenocarcinoma - immunology, Adenocarcinoma - pathology, Antibodies, Monoclonal - therapeutic use, B7-H1 Antigen - antagonists & inhibitors, B7-H1 Antigen - immunology, Cancer surgery, Cancer therapies, checkpoint inhibitor, CTLA-4 Antigen - antagonists & inhibitors, CTLA-4 Antigen - immunology, Esophagogastric Junction - immunology, Esophagogastric Junction - pathology, gastric, gastroesophageal, Humans, Immunotherapy, Metastasis, Monoclonal antibodies, PD‐1, Programmed Cell Death 1 Receptor - antagonists & inhibitors, Programmed Cell Death 1 Receptor - immunology, Randomized Controlled Trials as Topic, Stomach Neoplasms - drug therapy, Stomach Neoplasms - immunology, Stomach Neoplasms - pathology, Targeted cancer therapy